Prevalence of severe adverse events in health professionals after receiving the first dose of the COVID-19 vaccination in Togo, March 2021
Authors:
- Yao Rodion KonuYKYao Rodion Konu
- Fifonsi Adjidossi Gbeasor-KomlanviFGFifonsi Adjidossi Gbeasor-Komlanvi
- Arnold SadioASArnold Sadio
- Martin Kouame TchankoniMTMartin Kouame Tchankoni
- Wendpouire Ida Carine Zida-CompaoreWZWendpouire Ida Carine Zida-Compaore
- Kossivi Agbélénbko AfanviKAKossivi Agbélénbko Afanvi
- Mounerou SalouMSMounerou Salou
- Dadja Essoya LandohDLDadja Essoya Landoh
Preprint
Abstract
Introduction: Covid-19 vaccines can cause adverse events (AE) that can lead to increased hesitation or fear of vaccination. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals (HPs) vaccinated with COVISHIELD™ vaccine in Togo. Methods: A cross-sectional study was conducted from March 13 th to 19 th , 2021 in Togo among HPs who received the first dose of vaccine. An online self-administered questionnaire was used to collect data on sociodemographic characteristics and vaccination. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Regression analysis were performed to assess factors associated with SAEs. Results: A total of 1,639 HP (70.2% male) with a median age [IQR] of 32 years [27-40] participated. At least one AE was reported among 71.6% (95%CI= [69.3-73.8]). The most commonly reported AEs were pain at the injection site (91.0%), asthenia (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido was also reported in 3.0% of HP. Among HP who experienced AEs, 18.2% were unable to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were hospitalized. The SAE prevalence was 23.8% (95%CI= [21.8-25.9]). Being <30 years (aOR=5.54; p<0.001), or 30-49 years (aOR=3.62; p<0.001) and being female (aOR=1.97; p<0.001) were associated with SAEs. Conclusion: Despite the occurrence of SAEs, current data collected in Togo about adverse events are reassuring with COVISHIELD™ vaccine and how they could be managed. Key points: The prevalence of severe adverse events (SAEs) after COVID-19 vaccination was high among health professionals in Togo, especially in the youths (under 30years). Despite the occurrence of SAEs, current data collected in Togo about adverse events are reassuring with COVISHIELD(TM) vaccine and provide information about how the could be managed.Keywords
All Related Versions
- Published version: Archives of Public Health, 79 (1), 1.
This publication has 7 references indexed in Scilit:
- Acute Allergic Reactions to mRNA COVID-19 VaccinesJAMA, 2021
- First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Assessment of self-medication practices in the context of the COVID-19 outbreak in TogoBMC Public Health, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemicSafety Science, 2020
- Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in ChinaClinical Infectious Diseases, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020